SEC Comment Letter for Lineage Cell Therapeutics, (LCTX) — Mar 16, 2026
Lineage Cell Therapeutics, Inc.
Date: March 16, 2026 · CIK: 0000876343 · Accession: 0000000000-26-002663
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294202
Letter
Re: Lineage Cell Therapeutics, Inc. Registration Statement on Form S-3 Filed March 11, 2026 File No. 333-294202 Dear Brian Culley:
March 16, 2026
Brian Culley Chief Executive Officer Lineage Cell Therapeutics, Inc. 2173 Salk Avenue, Suite 200 Carlsbad, CA 92008
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Edwin Astudillo
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 16, 2026 Brian Culley Chief Executive Officer Lineage Cell Therapeutics, Inc. 2173 Salk Avenue, Suite 200 Carlsbad, CA 92008 Re: Lineage Cell Therapeutics, Inc. Registration Statement on Form S-3 Filed March 11, 2026 File No. 333-294202 Dear Brian Culley: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Edwin Astudillo </TEXT> </DOCUMENT>